Veteran investment executive with experience in private equity and corporate finance, focused on growth-stage technology and healthcare investments. Joseph Morrison was previously a partner at a mid-market PE firm and has led cross-border M&A, portfolio operational turnarounds, and value-creation programs. Holds an MBA with earlier investment banking experience; active board member emphasising EBITDA improvement, capital-structure optimization and disciplined exit planning.
Veteran investment executive with experience in private equity and corporate finance, focused on growth-stage technology and healthcare investments. Joseph Morrison was previously a partner at a mid-market PE firm and has led cross-border M&A, portfolio operational turnarounds, and value-creation programs. Holds an MBA with earlier investment banking experience; active board member emphasising EBITDA improvement, capital-structure optimization and disciplined exit planning.
Brings a private-equity mindset to growth-stage technology and healthcare investing, prioritizing companies with durable unit economics and clear pathways to EBITDA improvement. Focuses on hands-on value creation—operational turnarounds, go-to-market scaling and capital‑structure optimization—combined with disciplined underwriting and exit planning. Leverages cross-border M&A and corporate‑finance experience to structure flexible, mid‑to‑long horizon investments that balance revenue growth with margin restoration. Prefers control or influential minority positions where board-level intervention can accelerate operational change and de‑risk outcomes.
Brings a private-equity mindset to growth-stage technology and healthcare investing, prioritizing companies with durable unit economics and clear pathways to EBITDA improvement. Focuses on hands-on value creation—operational turnarounds, go-to-market scaling and capital‑structure optimization—combined with disciplined underwriting and exit planning. Leverages cross-border M&A and corporate‑finance experience to structure flexible, mid‑to‑long horizon investments that balance revenue growth with margin restoration. Prefers control or influential minority positions where board-level intervention can accelerate operational change and de‑risk outcomes.
| Trades 766 | Longs Won 573/766 74% | Profit Factor 29.51 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $5.67M |
| Average Win $635,574.72 | Best Trade (Mar 31) $140.19M | Sharpe Ratio -22.33 |
| Average Loss -$63,943.19 | Worst Trade (Sep 30) -$6.79M | Z-Score 13.79 (100%) |
| Commissions $0 | Avg. Trade Length 1y 10m 4d | Expectancy $459,325.43 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | 0.02% | 0.17% | 0.93% | 3.8% | 12.93% | 38.07% |
| Consecutive Losing Trades | 5,051 | 4,545 | 4,040 | 3,535 | 3,030 | 2,525 | 2,020 | 1,515 | 1,010 | 505 |